CYP2C19 and depressive symptom measurement: Similar to Świechowski et al. [39], Athreya et al. [56], conducting a predictive analysis with 1030 MDD patients of different ethnicities treated with citalopram and escitalopram, found that the CYP2C19 gene metabolization phenotypes were also not associated with these individuals’ clinical characteristics, such as severity of depression, nor their demographic characteristics.